Cytokinetics Inc.
- CYTK · Nasdaq
- Pharmaceutical Preparations
- South San Francisco, CA
- 673 employees
- CIK 0001061983
Updated from SEC filings through
Top things to know
Executives
-
Robert I. Blum Cytokinetics’ President and Chief Executive Officer 8-K, 2026-11-04 -
Sung Lee EVP, Chief Financial Officer 4, 2026-07-02 - Andrew Callos EVP, Chief Commercial Officer 4, 2026-08-31
- Jeffrey Hessekiel Chief Legal & Admin Officer 4, 2026-03-17
-
Fady Malik Executive Vice President, Research & Development 10-K, 2026-02-26 -
Eric Brown Vice President of Information Technology 10-K, 2026-02-26
What leadership is saying
“Our third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Cytokinetics Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in South San Francisco, CA. It trades as CYTK on Nasdaq. Revenue was $88.0M in the fiscal year ending December 31, 2025, +376.6% from the year before. It reported about 673 employees. Robert I. Blum is Cytokinetics’ President and Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $88.0M 10-K, 2026-02-26 | $18.5M 10-K, 2026-02-26 | $7.5M 10-K, 2026-02-26 | $94.6M 10-K, 2025-02-27 | $70.4M 10-K, 2024-02-28 |
| Operating income | -$612M 10-K, 2026-02-26 | -$536M 10-K, 2026-02-26 | -$496M 10-K, 2026-02-26 | -$324M 10-K, 2025-02-27 | -$186M 10-K, 2024-02-28 |
| SG&A | $284M 10-K, 2026-02-26 | $215M 10-K, 2026-02-26 | $174M 10-K, 2026-02-26 | $178M 10-K, 2025-02-27 | $96.8M 10-K, 2024-02-28 |
| Net income | -$785M 10-K, 2026-02-26 | -$590M 10-K, 2026-02-26 | -$526M 10-K, 2026-02-26 | -$389M 10-K, 2025-02-27 | -$215M 10-K, 2024-02-28 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Robert I. Blum Regional Commercial Real Estate Agent & Manager | Cytokinetics’ President and Chief Executive Officer | 8-K, 2026-11-04 |
| Sung Lee Chief Financial Officer | EVP, Chief Financial Officer | 4, 2026-07-02 |
| Andrew Callos EVP and Chief Commercial Officer at Cytokinetics | EVP, Chief Commercial Officer | 4, 2026-08-31 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 4, 2026-03-17 |
| Fady Malik | Executive Vice President, Research & Development | 10-K, 2026-02-26 |
| Eric Brown | Vice President of Information Technology | 10-K, 2026-02-26 |
| Fady Ibraham Malik | EVP Research & Development | 4, 2026-09-22 |
| Edward M. Kaye, M.D. | Board member (per proxy) bio: director | DEF 14A, 2026-04-17 |
| James M. Daly | Board member (per proxy) bio: member of our Board of Directors | DEF 14A, 2026-04-17 |
| John T. Henderson, M.B., Ch.B. | Board member (per proxy) bio: Chairman of our Board of Directors | DEF 14A, 2026-04-17 |
| Robert A. Harrington, M.D. | Board member (per proxy) bio: member of our Board of Directors | DEF 14A, 2026-04-17 |
What Cytokinetics Inc does
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 139.3 million (as of November 2, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $2.5B (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending December 31, 2025) | 10-K, February 26, 2026 |
| Latest proxy statement | Meeting May 27, 2026 (filed April 17, 2026) | DEF 14A, April 17, 2026 |
| Auditor | Ernst & Young LLP (San Jose, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 3, 2026 | Fady Ibraham Malik EVP Research & Development | Sale | 3,500 | $220K | Form 4, November 3, 2026 |
| November 2, 2026 | Robert I. Blum President & CEO | Sale | 7,500 | $471K | Form 4, November 2, 2026 |
| October 20, 2026 | Fady Ibraham Malik EVP Research & Development | Sale | 3,500 | $224K | Form 4, October 20, 2026 |
| October 12, 2026 | Robert I. Blum President & CEO | Sale | 7,500 | $472K | Form 4, October 13, 2026 |
| October 6, 2026 | Fady Ibraham Malik EVP Research & Development | Sale | 3,500 | $215K | Form 4, October 6, 2026 |
| September 28, 2026 | Robert I. Blum President & CEO | Sale | 7,500 | $491K | Form 4, September 28, 2026 |
| September 22, 2026 | Fady Ibraham Malik EVP Research & Development | Sale | 3,500 | $239K | Form 4, September 22, 2026 |
| September 15, 2026 | Robert E. Landry Director | Sale | 1,000 | $72K | Form 4, September 15, 2026 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-28
- Item 8.01 Other events
- 8-K filed 2026-08-13
- Item 8.01 Other events
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-27
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-08
- Item 8.01 Other events
- 8-K filed 2026-05-05
- Item 8.01 Other events
- 8-K filed 2026-05-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-24
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-17
- Item 8.01 Other events
Frequently asked questions about Cytokinetics Inc
- What does Cytokinetics Inc do?
- In its own words, from Item 1 of its 10-K: "We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function."
- What is Cytokinetics Inc's revenue?
- $88.0M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Cytokinetics Inc profitable?
- Cytokinetics Inc reported net income of -$785M for the fiscal year ending December 31, 2025.
- How many employees does Cytokinetics Inc have?
- About 673 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Cytokinetics Inc?
- Robert I. Blum, Cytokinetics’ President and Chief Executive Officer, as named in a 8-K filed November 4, 2026.
- Who is the CFO of Cytokinetics Inc?
- Sung Lee, EVP, Chief Financial Officer, as named in a 4 filed July 2, 2026.
- Where is Cytokinetics Inc headquartered?
- South San Francisco, CA.
- What is Cytokinetics Inc's stock ticker?
- CYTK on Nasdaq.
- What industry is Cytokinetics Inc in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Cytokinetics Inc's website?
- cytokinetics.com.
- When does Cytokinetics Inc report earnings next?
- February 5, 2027. Source: estimate_8k_pattern.
- Is Cytokinetics Inc a public company?
- Yes. Cytokinetics Inc files with the SEC under CIK 0001061983 and trades as CYTK.
- Who audits Cytokinetics Inc?
- Ernst & Young LLP, San Jose, California, as named in its latest annual report (10-K).
- How many shares of Cytokinetics Inc are outstanding?
- 139.3 million shares as of November 2, 2026, from its 10-Q filed November 4, 2026.
- What is Cytokinetics Inc's public float?
- $2.5B as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Cytokinetics Inc report?
- 1 reportable segment for the period ending December 31, 2025, from its 10-K filed February 26, 2026.
- When is Cytokinetics Inc's annual shareholder meeting?
- May 27, 2026, per its proxy statement (DEF 14A) filed April 17, 2026.
- Have Cytokinetics Inc insiders traded stock recently?
- Since September 2, 2025, officers and directors reported 92 open-market sales worth about $55.5M and 0 purchases on Forms 4 and 5. The most recent: Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares on November 3, 2026.